文献速递胸部肿瘤

不可切除非小细胞肺癌同步化疗联合放疗剂量递增试验的长期结果:NCCTG N0028(Alliance)

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
PubMed 文献 · J Thorac Oncol · 2017-01-12

本I/II期试验旨在确定胸部放疗的最大耐受剂量为74 Gy/37次,25例不可切除NSCLC患者接受2 Gy每日分割同步每周卡铂和紫杉醇治疗,中位生存42.5个月、5年生存率20%,III期患者中位生存39.8个月、5年生存率15%。作者认为III期患者生存较好可能与放疗计划中央审核确保方案依从性及心脏受照剂量很低有关。

要点

  • 最大耐受剂量为74 Gy/37次,25例不可切除NSCLC接受2 Gy每日分割同步每周卡铂和紫杉醇。
  • 所有患者中位生存42.5个月、5年生存率20%;III期患者中位生存39.8个月、5年生存率15%。
  • I/II期患者中位生存52.9个月、5年生存率40%。

核心结论

  • III期患者的中位生存相当有利,作者认为这可能归因于治疗前放疗计划的严格中央审核确保方案依从性以及心脏受照剂量很低。
  • 进一步改善5年生存可能需要对全身治疗和胸部放疗两方面进行研究。
  • 可能有助于这些努力的潜在治疗方式包括免疫治疗、靶向治疗、改进影像、自适应放疗、同步整合推量技术、新型剂量分割方案和带电粒子治疗。

研究设计与样本

  • 本I/II期试验旨在确定作为综合治疗一部分的胸部放疗最大耐受剂量,本报告包括该研究中患者的长期结局。
  • II期部分从未完成,因为在结束前RTOG-0617已开放。
  • 本研究中最大耐受剂量定义为74 Gy放疗分37次。
  • 25例不可切除NSCLC患者接受2 Gy每日分割和同步每周卡铂和紫杉醇治疗。
  • 这些患者中20例为III期疾病,5例为I或II期疾病。

主要发现

  • 患者随访至死亡或存活者至少5年。
  • 所有患者的中位生存和5年生存率分别为42.5个月和20%。
  • I或II期患者的中位生存和5年生存率分别为52.9个月和40%。
  • III期患者的中位生存和5年生存率分别为39.8个月和15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • II期部分从未完成,因为在结束前RTOG-0617已开放。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This phase I/II trial was designed to determine the maximally tolerated dose of thoracic radiotherapy as part of a combined modality approach. This report includes the long-term outcomes of patients treated on this study. The phase II portion was never completed, as RTOG-0617 opened before it was concluded. METHODS: In this study, the maximally tolerated dose was defined as 74 Gy of radiation in 37 fractions. Twenty-five patients with unresectable NSCLC were treated with 2-Gy daily fractions and concurrent weekly carboplatin and paclitaxel. Of these patients, 20 had stage III disease and five had stage I or II disease. RESULTS: Patients were followed until death or for a minimum of 5 years in the case of survivors. The median and 5-year survivals were 42.5 months and 20% for all patients, 52.9 months and 40% in patients with stages I or II disease, and 39.8 months and 15% in patients with stage III disease. CONCLUSIONS: The median survival of the stage III patients was quite favorable. We believe that this may have been due to a robust central review program of radiotherapy plans before treatment, ensuring compliance with protocol guidelines along with very low exposure of the heart to radiotherapy. Further improvements in 5-year survival will likely require research on both systemic therapy and thoracic radiotherapy. Potential therapeutic modalities that may aid in these efforts include immunotherapy, targeted therapy, improved imaging, adaptive radiotherapy, simultaneous integrated boost techniques, novel dose fractionation regimens, and charged particle therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Schild SE, Hillman SL, Tan AD, et al. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol. 2017. PMID: 28089762. doi:10.1016/j.jtho.2016.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。